Volume 2.00 | Jan 7

Mammary Cell News 2.00, January 7, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Blocking Inflammation Receptor Kills Breast Cancer Stem Cells
Researchers identified a receptor, CXCR1, on the cancer stem cells which triggers growth of stem cells in response to inflammation and tissue damage. [University of Michigan Comprehensive Cancer Center, Ann Arbor]

Watch Procedure Now  
Learn to Enumerate Mammospheres and Tumorspheres
Cultured in MammoCult®
by STEMCELL Technologies


‘Junk DNA’ Could Spotlight Breast and Bowel Cancer
Scientists at The University of Nottingham have found that a group of genetic rogue elements, produced by DNA sequences commonly known as ‘junk DNA’, could help diagnose breast and bowel cancer. [The University of Nottingham, Nottingham]

Lombardi Researchers Find Investigational Agent Reduces Tumor Resistance to Breast Cancer Therapy
Researchers have found a way to cleverly override signals that tell breast cancer cells to keep surviving in the face of anticancer treatment. [Georgetown University, Washington, DC]

Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer
Bionovo, Inc. announced the publication of results from its study on the anti-tumor mechanism of BN107. The results of the study, describe the potential molecular mechanisms mediating the selective pro-apoptotic effect induced by BN107 on estrogen receptor negative breast cancer cells. [Bionovo, Inc., Emeryville]




Complex Landscapes of Somatic Rearrangement in Human Breast Cancer Genomes
The study provides a new perspective on cancer genomes, highlighting the diversity of somatic rearrangements and their potential contribution to cancer development. [Nature]

CXCR1 Blockade Selectively Targets Human Breast Cancer Stem Cells in vitro and in Xenografts
Scientists report the development of a strategy to target breast cancer stem cells through blockade of the IL-8 receptor CXCR1. [J Clin Invest]

Aldehyde Dehydrogenase 1 – Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer
Results suggest that the metastatic, aggressive behavior of inflammatory breast cancer may be mediated by a cancer stem cell component that displays aldehyde dehydrogenase enzymatic activity. [Clin Cancer Res]

Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated Necrosis
Researchers show the integrated roles of the antiapoptotic BCL-W and BCL2 in affecting responsiveness to the antiestrogen ICI 182,780 (ICI; Fulvestrant Faslodex), using both molecular (siRNA; shRNA) and pharmacologic (YC137) approaches in three breast cancer variants. [PLoS ONE]

Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
An elevated level of the receptor tyrosine kinase Eph receptor A2 was found to be an important contributor to trastuzumab resistance. [Cancer Res]

Investigating AP-2 and YY1 Protein Expression as a Cause of High HER2 Gene Transcription in Breast Cancers with Discordant HER2 Gene Amplification
Candidacy for anti-HER2 adjuvant therapy in breast cancer is assessed using tumour HER2 status but recently it has been proposed that the transcription factors AP-2alpha and YY1 may cause HER2 protein overexpression independently of gene amplification. [Breast Cancer Res]


Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
Trastuzumab, docetaxel and capecitabine, when taken together, is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids. [J Clin Oncol]

A Randomized Phase II Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer
The 96-hour paclitaxel regimen did not significantly improve response or time to disease progression, was more cumbersome to administer, and was associated with greater myelosuppression (but less neuropathy and myalgia) compared with the 3-hour schedule. [Cancer]



OncoMed Pharmaceuticals, Inc. and Fluidigm Corporation Announce Strategic Collaboration
OncoMed Pharmaceuticals, Inc. and Fluidigm Corporation today announced a new initiative to apply Fluidigm’s unique microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells.

United Kingdom National Stem Cell Network (UKNSCN) Funding and New Management Structure Announced
The UKNSCN is delighted to announce that its Research Council sponsors – BBSRC, MRC, EPSRC and ESRC – have increased their core funding of the Network to £180k per annum for the next two financial years.


US Food and Drug Administration Broadens Clearance for Agendia’s MammaPrint
Agendia announced that the US Food and Drug Administration cleared its MammaPrint breast cancer recurrence test for all ages. [Agendia, United States]

Independent Scientist Award (Parent K02) (PA-10-057)  [National Institutes of Health, United States]

Academic Career Award (Parent K07) (PA-10-058) [National Institutes of Health, United States]

Mentored Clinical Scientist Research Career Development Award (Parent K08) (PA-10-059) [National Institutes of Health, United States]

Cancellation of Notice NOT-CA-09-017, Clarification of Page Limitations for Research Plan in PAR-09-026 Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment (U01) (NOT-OD-10-029) [National Institutes of Health, United States]

Notice on P40 Page Limits (NOT-RR-10-002) [National Institutes of Health, United States]

Academic Research Enhancement Award (Parent R15) (PA-10-070) [National Institutes of Health, United States]

Technologies and Software to Support Integrative Cancer Biology Research (R43/R44) [Small Business Innovation Research, United States]


BIT’s 3rd Annual World Cancer Congress 2010 – Breast Cancer Conference
April 25-27, 2010
Shanghai, China

IMPAKT Breast Cancer Conference
May 6-8, 2010
Brussels, Belgium

Breast Cancer Research 2010 Conference
May 18, 2010
London, United Kingdom

Gordon Research Conference: Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy

12th Milan Breast Cancer Conference
June 16-18, 2010
Milan, Italy

The 21st Meeting of the European Association for Cancer Research
June 26-29, 2010
Oslo, Norway

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Data Entry Assistant – Marketing (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us